XETRA - Delayed Quote EUR

Merck & Co., Inc. (6MK.DE)

Compare
97.70
+0.50
+(0.51%)
At close: January 10 at 5:35:38 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
63,174,000.00
60,115,000.00
59,283,000.00
48,704,000.00
41,518,000.00
Cost of Revenue
15,277,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Gross Profit
47,897,000.00
43,989,000.00
41,872,000.00
35,078,000.00
27,900,000.00
Operating Expense
33,737,000.00
41,035,000.00
23,590,000.00
21,879,000.00
22,352,000.00
Operating Income
14,160,000.00
2,954,000.00
18,282,000.00
13,199,000.00
5,548,000.00
Net Non Operating Interest Income Expense
-914,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
Other Income Expense
474,000.00
-284,000.00
-1,033,000.00
1,450,000.00
1,087,000.00
Pretax Income
13,720,000.00
1,889,000.00
16,444,000.00
13,879,000.00
5,863,000.00
Tax Provision
1,557,000.00
1,512,000.00
1,918,000.00
1,521,000.00
1,340,000.00
Net Income Common Stockholders
12,148,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Diluted NI Available to Com Stockholders
12,148,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Basic EPS
4.79
0.14
5.73
5.16
2.79
Diluted EPS
4.78
0.14
5.71
5.14
2.78
Basic Average Shares
2,534,000.00
2,607,142.86
2,532,000.00
2,530,000.00
2,530,225.83
Diluted Average Shares
2,542,500.00
2,607,142.86
2,542,000.00
2,538,000.00
2,541,000.00
Total Expenses
49,014,000.00
57,161,000.00
41,001,000.00
35,505,000.00
35,970,000.00
Net Income from Continuing & Discontinued Operation
12,148,000.00
365,000.00
14,519,000.00
13,049,000.00
7,067,000.00
Normalized Income
12,664,838.85
861,910.00
16,278,819.00
11,470,617.41
4,042,522.00
Interest Income
339,000.00
365,000.00
157,000.00
36,000.00
59,000.00
Interest Expense
1,253,000.00
1,146,000.00
962,000.00
806,000.00
831,000.00
Net Interest Income
-914,000.00
-781,000.00
-805,000.00
-770,000.00
-772,000.00
EBIT
14,973,000.00
3,035,000.00
17,406,000.00
14,685,000.00
6,694,000.00
EBITDA
19,239,000.00
6,907,000.00
21,315,000.00
17,899,000.00
10,180,000.00
Reconciled Cost of Revenue
15,277,000.00
16,126,000.00
17,411,000.00
13,626,000.00
13,618,000.00
Reconciled Depreciation
4,266,000.00
3,872,000.00
3,909,000.00
3,214,000.00
3,486,000.00
Net Income from Continuing Operation Net Minority Interest
12,148,000.00
365,000.00
14,519,000.00
12,345,000.00
4,519,000.00
Total Unusual Items Excluding Goodwill
-583,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Total Unusual Items
-583,000.00
-629,000.00
-1,993,000.00
982,000.00
618,000.00
Normalized EBITDA
19,822,000.00
7,536,000.00
23,308,000.00
16,917,000.00
9,562,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-66,161.15
-132,090.00
-233,181.00
107,617.41
141,522.00
12/31/2020 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IDP.DE Biogen Inc.
144.80
-0.34%
 
C43.DE Cosmo Pharmaceuticals N.V.
69.00
+0.73%
 
4AB.DE AbbVie Inc.
172.44
+0.44%
 
GIS.DE Gilead Sciences, Inc.
87.37
+1.35%
 
7XP.F Organon & Co.
15.54
+1.17%
 
BRM.DE Bristol-Myers Squibb Company
54.92
+0.02%
 
SNW.DE Sanofi
95.46
-0.89%
 
GS71.DE GSK plc
16.24
-0.18%
 
ZEG.DE AstraZeneca PLC
131.25
+0.04%
 
JNJ.DE Johnson & Johnson
139.68
+1.13%